Watch ATYR. Know when insiders buy.
One email the day a filing lands. Free.
ATYR
aTYR PHARMA INC
0.50
−0.01 −1.39%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
58
WATCH · shorts 58
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $48.7MP/E —DIV YIELD —FCF YIELD -112.45%REV TTM —NET INCOME −$60.8MNET CASH $10.4M52W 0.40 – 6.03SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$10.9M | −$10.3M | — | -0.11 | −$9.4M | $73K | −$9.4M | Aug 7 |
| Q1 2026 · Mar 31 | — | — | — | −$11.4M | −$10.8M | — | -0.11 | −$12.5M | $138K | −$12.7M | May 15 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$14.8M | −$14M | — | -0.14 | −$12.2M | $31K | −$12.2M | Mar 5 |
| Q3 2025 · Sep 30 | $190K | — | — | −$26.7M | −$25.7M | — | -0.26 | −$20.5M | $37K | −$20.5M | Nov 6 |
| Q2 2025 · Jun 30 | $0 | — | — | −$20.3M | −$19.5M | — | -0.22 | −$13.9M | $9K | −$13.9M | Aug 7 |
| Q1 2025 · Mar 31 | $0 | −100.0% | — | −$15.8M | −$14.9M | — | -0.17 | −$15.4M | $0 | −$15.4M | May 15 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$15.8M | −$15M | — | -0.17 | −$13.1M | $25K | −$13.2M | Mar 5 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$18.1M | −$17.3M | — | -0.23 | −$13.2M | $15K | −$13.2M | Nov 6 |
| Q2 2024 · Jun 30 | $0 | — | — | −$17.3M | −$16.3M | — | -0.23 | −$20.4M | $8K | −$20.5M | Aug 7 |
| Q1 2024 · Mar 31 | $235K | — | — | −$16.6M | −$15.5M | — | -0.23 | −$22.4M | $17K | −$22.4M | May 7 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$16M | −$14.8M | — | -0.25 | −$11.1M | $17K | −$11.1M | Mar 5 |
| Q3 2023 · Sep 30 | $353K | — | — | −$12.6M | −$11.3M | — | -0.20 | −$9.6M | $557K | −$10.1M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $190K | — | −$77.6M | −$74.1M | -39009.5% | -0.80 | −$62M | $77K | −$62.1M | — | — |
| FY2024 · to Dec 31 | $235K | — | −$67.9M | −$64M | -27243.8% | -0.86 | −$69.1M | $65K | −$69.2M | — | — |
| FY2023 · to Dec 31 | $353K | — | −$54.9M | −$50.4M | -14274.5% | -0.94 | −$33.2M | $4.2M | −$37.4M | — | — |
| FY2022 · to Dec 31 | $10.4M | — | −$46.4M | −$45.3M | -436.5% | -1.60 | −$41.9M | $1.6M | −$43.5M | — | — |
| FY2021 · to Dec 31 | $0 | — | −$34M | −$33.8M | — | -1.77 | −$33.1M | $192K | −$33.3M | — | — |
| FY2020 · to Dec 31 | $10.5M | — | −$15.9M | −$16.2M | -155.2% | -1.77 | −$15.3M | $202K | −$15.5M | — | — |
Every number comes from aTYR PHARMA INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.